Should criteria for inclusion in cancer clinical trials be expanded?
Division of Hematology-Oncology, 5323 Harry Hines Blvd, 8852, Dallas, TX 75390-8852, USA.|Harold C Simmons Cancer Center, 5323 Harry Hines Blvd, 8590, Dallas, TX 75390-8590, USA.
David E
DE
Gerber
Harold C Simmons Cancer Center, 5323 Harry Hines Blvd, 8590, Dallas, TX 75390-8590, USA.|Department of Clinical Sciences, 5323 Harry Hines Blvd, 9066, Dallas, TX 75390-9066, USA.
Sandi L
SL
Pruitt
Harold C Simmons Cancer Center, 5323 Harry Hines Blvd, 8590, Dallas, TX 75390-8590, USA.|Department of Clinical Sciences, 5323 Harry Hines Blvd, 9066, Dallas, TX 75390-9066, USA.|Division of General Internal Medicine, 5323 Harry Hines Blvd, 8548, Dallas, TX 75390-8548, USA.
Ethan A
EA
Halm
D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D018579:Patient Selection
accrual; cancer; clinical trials; eligibility; enrollment; exclusion criteria